Skip to content
Download PDF

Whipple Disease

Chapter 181 | Part 5: Infectious Diseases · Part 5 – Infectious Diseases: Bacterial · Chapter 181

Key Clinical Points

  1. Whipple disease (WD) is a chronic infection caused by Tropheryma whipplei, characterized by the triad of arthralgias, weight loss, and chronic diarrhea.
  2. Histologic hallmark: Infiltration of lamina propria with macrophages containing PAS-positive inclusions resistant to diastase.
  3. Neurologic involvement occurs in ~50% of patients; it portends a poor prognosis and is the most common site for relapse.
  4. Cardiac involvement (endocarditis) is often culture-negative and may be complicated by heart failure or embolic events.
  5. Saliva and fecal PCR are indicators of colonization, not disease; they have low positive predictive values and should not be used as sole diagnostic tools.
  6. TMP-SMX monotherapy is insufficient for long-term management because TMP is not active against T. whipplei (due to lack of dihydrofolate reductase).
  7. Genetic risk factors include HLA-DRB1(13) and DQB1(06), as well as IRF4 haploinsufficiency.
  8. Clinical progression typically involves an initial period of arthralgias/arthritis (6–8 years) before gastrointestinal symptoms emerge.
  9. Optimal CNS treatment requires high-dose IV ceftriaxone or meropenem followed by long-term oral doxycycline or minocycline plus hydroxychloroquine.
  10. Multisystemic involvement is common; any organ can be affected, and WD should be suspected in cases of chronic multisystemic disease.

DEFINITION & CLASSIFICATION

• Definition (Harrison's 22e): Whipple disease (WD) is a chronic infection caused by Tropheryma whipplei. • History: Identified in 1907; confirmed as bacterial via electron microscopy (1960s) and 16S rRNA PCR sequencing (1991). • Clinical Presentation: Characterized by a combination of arthralgias/arthritis, weight loss, chronic diarrhea, and fever.

• Classification: ◦ Classic WD: Chronic infection defined by involvement of the duodenum and/or jejunum that develops over years. ◦ Isolated Infection: Infection in the absence of intestinal symptoms (e.g., endocarditis, neurologic disease, uveitis, rheumatologic manifestations, pulmonary involvement).

EPIDEMIOLOGY

• Prevalence: Rare; estimated at 10 cases per million in the U.S. • Exposure: ~50% of Western Europeans and ~75% of Africans (rural Senegal) have been exposed to T. whipplei. • Demographics: More common in males, Caucasians, and individuals with increasing age. • Transmission: Likely fecal-oral; evidence includes presence in sewage water and high detection rates among family members of carriers.

Carriage Rates

• Asymptomatic Carriage: Much higher than chronic infection rates (<0.01% of those exposed). • Detection Sites: Stool (1–11%) is more common than saliva (0.2%). • Risk Factors: Higher prevalence in individuals with sewage exposure (12–26%) and children in tropical Africa/Asia (20–48%). • Duration: Carriage can persist for many years (e.g., 7 years reported in a sewer worker). • Bacterial Load: Lower in asymptomatic carriage than in active disease.

ETIOLOGY & PATHOPHYSIOLOGY

• Organism Characteristics: ◦ Weakly staining gram-positive bacillus. ◦ Small chromosome (100 genotypes identified; all capable of causing similar syndromes). ◦ Host-dependent intracellular pathogen with a tropism for myeloid cells.

• Host Factors & Immunology: ◦ Genetic Risk: HLA-DRB1(13) and DQB1(06) (favor humoral over cell-mediated response); IRF4 haploinsufficiency (autosomal dominant, incomplete penetrance). ◦ Immune Profile: Impaired T1 response, increased anti-inflammatory cytokines, increased regulatory T cell activity, and M2 macrophage polarization. ◦ Cellular Deficits: Reduced macrophage antimicrobial activity, impaired phagosome–lysosome fusion, and blunted development of T. whipplei-specific T cells. ◦ Impact of Therapy: Treatments that blunt cell-mediated immunity (e.g., glucocorticoids or anti-TNF-α) may accelerate disease progression.

CLINICAL FEATURES

• Acute Infection: May present as acute gastroenteritis in children, acute pneumonia, or a febrile syndrome (sometimes co-infected with Giardia lamblia). • Chronic Infection (Classic WD): ◦ Initial Phase: Often lasts 6–8 years; characterized by intermittent, symmetrical, migratory oligo- or polyarthralgias/seronegative arthritis (knees, wrists, ankles, MCP/IP joints). ◦ Intestinal Phase: Characterized by diarrhea, weight loss, and potentially fever/abdominal pain. ◦ Systemic Findings: Occult GI blood loss, vitamin deficiencies, hepatosplenomegaly (10–15%), ascites (10%), anemia, and hypereosinophilia. ◦ Imaging: Common finding of mesenteric/retroperitoneal lymphadenopathy; FDG-PET may show extensive small bowel involvement.

Neurologic Disease

• Prevalence: ~50% of patients; often asymptomatic but portends poor prognosis. • Common Manifestations: Cognitive changes (memory loss to dementia), personality/mood alterations, hypothalamic involvement (polyuria/polydipsia, sleep-cycle disorders), and supranuclear ophthalmoplegia. ◦ Specific Signs: Supranuclear gaze palsy (usually vertical), oculomasticatory and oculofacial myorhythmia (highly suggestive of WD), nystagmus, retrobulbar neuritis. • Focal/Other: Seizures, ataxia, meningitis, encephalitis, hydrocephalus, myoclonus, choreiform movements, distal polyneuropathy. • Imaging: MRI may show T2/FLAIR hyperintense lesions (median temporal lobe, midbrain, hypothalamus, thalamus) with potential gadolinium enhancement. • CSF Analysis: Often normal; if abnormal, typically shows lymphocyte-predominant leukocytosis and elevated protein; occasionally low glucose.

Cardiac Disease

• Endocarditis: Found in 85% of males; accounts for 2.6–6.3% of culture-negative endocarditis cases. ◦ Complications: Congestive heart failure (40%), embolic events, arrhythmias, mycotic aneurysm, or hypotension. • Clinical Presentation: Fever is often absent; Duke criteria are rarely met. • Echocardiography: Vegetations seen in 50–75% of cases; most common sites are aortic and mitral valves. • Other Findings: Mural/myocardial/aortic disease, pericardial disease, or constrictive pericarditis.

Pulmonary Disease

• Presentation: Combination of interstitial disease, nodules, parenchymal infiltrate, and pleural effusion. • Complications: Associated with pulmonary hypertension. • Note: T. whipplei in BALF of asymptomatic HIV patients does not necessarily correlate with inflammation or decreased lung function.

Lymphatic Disease

• Common Findings: Mesenteric and retroperitoneal lymphadenopathy (with intestinal disease); mediastinal adenopathy (with pulmonary infection).

Ocular Disease

• Uveitis: Most common; can be anterior, intermediate, or posterior. ◦ Warning: Glucocorticoid use alone may worsen uveitis and unmask extraocular disease.

Dermatologic Disease

• Melanoderma: Skin hyperpigmentation in light-exposed areas (without adrenal dysfunction). ◦ Other: Erythematous macular lesions, nonthrombocytopenic purpura, subcutaneous nodules, hyperkeratosis.

Miscellaneous Sites

• Multisystemic Nature: Can involve thyroid, renal, testicular, epididymal, gallbladder, skeletal muscle, bone marrow, and membranous nephropathy. ◦ Clinical Rule: The combination of rheumatologic and intestinal disease with weight loss warrants high suspicion for WD.

DIFFERENTIAL DIAGNOSIS

• Isolated Infection: Often presents as endocarditis, neurologic disease, uveitis, or pulmonary involvement without initial intestinal symptoms. • Intestinal Mimics: Crohn disease, celiac disease. • Systemic Mimics: Sarcoidosis, Behçet’s disease.

DIAGNOSTIC APPROACH

  1. Histology (Primary Diagnostic Step): • Perform duodenal biopsy; look for infiltration of lamina propria with macrophages containing PAS-positive inclusions resistant to diastase. • Note: PAS is non-specific (also positive in mycobacteria); IHC has higher specificity/sensitivity than PAS.
  2. Molecular Testing (PCR): • Duodenal biopsy: Use PCR; a cycle threshold value of ≤30 confirms diagnosis even if PAS is negative. • Body Fluids: Urine PCR (75% sensitivity) or CSF/synovial fluid PCR to support findings. • Note: Saliva and fecal PCR are for colonization only; not sufficient as sole diagnostic tools.
  3. Imaging: • FDG-PET: Used to assess extent of small bowel involvement and guide tissue sampling.
  4. Other Tests: • Electron Microscopy: Identifies trilaminar cell wall (complementary). • Serology: Generally low value due to poor IgM/IgG response in active infection.

MANAGEMENT & TREATMENT

  1. Initial / CNS-Optimized Phase: • For patients with CNS or other critical site involvement, initiate high-dose IV therapy. • Ceftriaxone: 2 g IV q12h OR Meropenem: 2 g q8h. • Duration: 2–4 weeks.
  2. Maintenance Phase: • Transition to oral therapy for at least 1 year. • Option A: Oral Doxycycline (100 mg twice a day). • Option B: Minocycline plus Hydroxychloroquine (200 mg three times a day; used to raise phagosome pH and increase drug activity).
  3. Monitoring & Precautions: • TMP-SMX Warning: Avoid TMP-SMX monotherapy for critical sites as it leads to high relapse rates; TMP is not active against T. whipplei due to lack of dihydrofolate reductase. • Duration: Long-term treatment (≥1 year) is required to manage risk of relapse and reinfection.

KEY PEARLS & HIGH-YIELD POINTS

• Diagnostic Rule: A negative PCR does not exclude WD; pretest probability is critical. • Clinical Pearl: If a patient presents with rheumatologic symptoms and later develops diarrhea/weight loss, suspect WD. • Treatment Logic: Use high-dose IV Ceftriaxone or Meropenem for CNS involvement to ensure rapid response, followed by long-term oral Doxycycline or Minocycline + Hydroxychloroquine.